Ryan Cohlhepp Sells 12,500 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 12,500 shares of the company’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $20.29, for a total transaction of $253,625.00. Following the completion of the transaction, the chief operating officer owned 191,641 shares of the company’s stock, valued at $3,888,395.89. This trade represents a 6.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Wednesday, April 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $23.01, for a total transaction of $287,625.00.
• On Monday, March 16th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $19.66, for a total transaction of $245,750.00.
• On Tuesday, March 3rd, Ryan Cohlhepp sold 17,392 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.16, for a total transaction of $315,838.72.

Bicara Therapeutics Trading Down 4.6%

NASDAQ BCAX traded down $0.94 during trading on Monday, hitting $19.29. The company had a trading volume of 571,810 shares, compared to its average volume of 531,321. Bicara Therapeutics Inc. has a one year low of $7.80 and a one year high of $24.25. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -6.94 and a beta of -0.57. The company’s fifty day moving average is $21.01 and its 200-day moving average is $18.20.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). As a group, equities analysts anticipate that Bicara Therapeutics Inc. will post -3.37 EPS for the current year.

Institutional Trading of Bicara Therapeutics

Several institutional investors have recently bought and sold shares of the company. Deutsche Bank AG grew its position in Bicara Therapeutics by 0.9% during the 4th quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock valued at $2,165,000 after purchasing an additional 1,171 shares during the last quarter. Legal & General Group Plc grew its position in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares during the last quarter. Mariner LLC grew its position in Bicara Therapeutics by 3.0% during the 4th quarter. Mariner LLC now owns 64,562 shares of the company’s stock valued at $1,087,000 after purchasing an additional 1,902 shares during the last quarter. Invesco Ltd. grew its position in Bicara Therapeutics by 13.2% during the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock valued at $157,000 after purchasing an additional 1,962 shares during the last quarter. Finally, Quantinno Capital Management LP grew its position in Bicara Therapeutics by 16.1% during the 1st quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock valued at $350,000 after purchasing an additional 2,447 shares during the last quarter.

Analyst Ratings Changes

A number of analysts have recently weighed in on BCAX shares. The Goldman Sachs Group upped their target price on shares of Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. HC Wainwright upped their target price on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Wells Fargo & Company upped their target price on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Tuesday, March 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Wednesday, April 8th. Finally, Wall Street Zen downgraded shares of Bicara Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $30.27.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.